October 28, 2025
DurAVR® THV Clinical Data Update at TCT 2025
At TCT, Dr. Rishi Puri presented data from DurAVR® THV clinical experience, demonstrating a favorable hemodynamic profile for 37 patients sustained to 1-year follow-up.
One-year Results Highlights:
- DurAVR® THV demonstrated a favorable hemodynamic profile sustained to one-year, with an Effective Orifice Area (EOA) of 2.1 ± 0.2 cm2, a Mean Pressure Gradient (MPG) of 8.6 ± 2.6 mmHg and Doppler Velocity Index (DVI) of 0.58.
- At one-year, clinical safety outcomes show positive results with no valve or cardiovascular related mortality and, importantly, no prosthesis-patient mismatch (PPM) reported in these small annuli patients (aortic annulus area 395.80 ± 37.26mm2) at one-year follow-up.